Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 19:16:39·⟳ 抓取 19:17:18 +39s·⚡ 决策 10-15 19:19:25 +2m07s·11.9 天前
Insmed 宣布启动 TPIP 四项 III 期 PALM 项目，但核心试验启动早已披露、无数据无近期收入
这是已知管线的程序性进展打包发布：PALM-PAH 已于 2026 年 4 月启动、PALM-ILD 持续入组（公司 2026 年 5 月日文公告及 8 月 Q2 更新均已披露），本条仅新增 PPF 启动与 IPF 时间表，无 topline 数据、无监管突破、无近期收入；盘前 INSM 反而小跌约 1.7%，市场未视为利好。无预期差、无正 edge，不做多；事件本身非利空，也不做空。
📄 原文Investing.com↗ 原文
Insmed launches four phase 3 trials for lung disease therapy
Can robust TSMC earnings help settle AI jitters? BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM) announced today…
不做 Insmed Incorporated（INSM.US）
无增量事实：PALM-PAH 2026 年 4 月已启动、PALM-ILD 已在入组、TPIP 峰值预期 8 月已披露，本条为 CHEST 会议层面的项目再包装；无临床数据、无监管节点、距收入数年，盘前小跌约 1.7% 确认无预期差，不具备多空任一方的短线 edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Insmed 的 TPIP 四项 III 期是早已启动/披露的在研管线的会议层面再包装，无临床数据或监管状态迁移，距商业化数年；盘前股价小跌确认无增量惊喜，不具可交易 edge，回避。
消息传播链
- 聚合站转述公司在 CHEST 2026 公布的 PALM 四项 III 期项目，未提供新疗效数据；Investing.com 非首发原始渠道，未定位到当日公司 IR 原文市场反应:截至 2026-10-15 07:17 ET 盘前 INSM 报 96.10 美元，较前收 97.79 跌约 1.73%，盘前量仅 240 股
关键理由
- III 期启动只是 II 期阳性后的既定执行步骤，PALM-PAH 早在 2026 年 4 月已启动，本条不构成新的风险消除或预期上修
主要风险
- 若 CHEST 2026 同时披露未被新闻稿涵盖的强阳性新数据，可能改变判断；III 期 24–104 周后才读出，期间无近期催化
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-15 · 影响 supports
未发现本次 CHEST 公布伴随新疗效/安全性数据的报道，仅为试验设计与启动信息；盘前股价 -1.7%，无利好定价
检索:Insmed TPIP PALM Phase 3 topline data CHEST 2026 new results 原文 ↗
先例如何影响了这次决策
对本次决策的影响:支持 AVOID：即使同类启动事件历史上偶有正向反应，也不适用于一个核心内容已在数月前披露的再包装公告
方向:未构建先例面板：结论基于'无新增事实'（核心 III 期早已启动、无数据读出），而非对 III 期启动类事件历史涨幅的判断
涨幅量级:不适用：无 ENTER 计划，不需要校准幅度
形态:医药经验先验显示'临床启动/推进'类程序性里程碑通常无短线重定价，真正催化为 topline 读出与监管节点；本案盘前小跌与之一致
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`insm palm-pah palm-ild palm-ppf palm-ipf trial initiation | insmed palm phase 3 treprostinil palmitil inhalation powder | insmed 曲前列尼尔 棕榈酸酯 吸入粉雾剂 三期临床`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不 - fetch_decision_experience 成功 stock_tools_inprocess · 5 ms
{ - web_search 成功 doubao_search · 2,909 ms
豆包搜索结果（原始查询:Insmed PALM program treprostinil palmitil Phase 3 initiation announcement；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 1,103 ms
{
原文全文
展开原文 · 2,032 字
Can robust TSMC earnings help settle AI jitters?
BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM) announced today the launch of its PALM Clinical Development Program, which includes four Phase 3 studies evaluating treprostinil palmitil inhalation powder as a once-daily therapy for patients with pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis, according to a press release statement.
Three of the four studies, PALM-PAH, PALM-ILD, and PALM-PPF, have been initiated. The fourth study, PALM-IPF, is expected to begin in the first half of 2027. The program aims to enroll more than 2,000 patients across the four studies.
PALM-PAH is a 24-week study evaluating the therapy in patients with WHO Group 1 pulmonary hypertension. The primary endpoint is change from baseline in 6-minute walk distance at Week 24.
PALM-ILD is a 24-week study evaluating the therapy in patients with WHO Group 3 pulmonary hypertension. The primary endpoint is change from baseline in 6-minute walk distance at Week 24.
PALM-PPF is a 52 to 104-week study evaluating the therapy in adult patients with progressive pulmonary fibrosis. The primary endpoint is change from baseline in absolute forced vital capacity at Week 52.
PALM-IPF will be a 52 to 104-week study evaluating the therapy in adult patients with idiopathic pulmonary fibrosis. The primary endpoint will be change from baseline in absolute forced vital capacity at Week 52.
Treprostinil palmitil inhalation powder is an investigational dry powder formulation of treprostinil palmitil, a pro-drug formulation of inhaled treprostinil. The therapy is administered in a capsule-based inhalation device and has not been approved for any indication in any jurisdiction.
The company presented the program at the American College of Chest Physicians Annual Meeting 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM) announced today the launch of its PALM Clinical Development Program, which includes four Phase 3 studies evaluating treprostinil palmitil inhalation powder as a once-daily therapy for patients with pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis, according to a press release statement.
Three of the four studies, PALM-PAH, PALM-ILD, and PALM-PPF, have been initiated. The fourth study, PALM-IPF, is expected to begin in the first half of 2027. The program aims to enroll more than 2,000 patients across the four studies.
PALM-PAH is a 24-week study evaluating the therapy in patients with WHO Group 1 pulmonary hypertension. The primary endpoint is change from baseline in 6-minute walk distance at Week 24.
PALM-ILD is a 24-week study evaluating the therapy in patients with WHO Group 3 pulmonary hypertension. The primary endpoint is change from baseline in 6-minute walk distance at Week 24.
PALM-PPF is a 52 to 104-week study evaluating the therapy in adult patients with progressive pulmonary fibrosis. The primary endpoint is change from baseline in absolute forced vital capacity at Week 52.
PALM-IPF will be a 52 to 104-week study evaluating the therapy in adult patients with idiopathic pulmonary fibrosis. The primary endpoint will be change from baseline in absolute forced vital capacity at Week 52.
Treprostinil palmitil inhalation powder is an investigational dry powder formulation of treprostinil palmitil, a pro-drug formulation of inhaled treprostinil. The therapy is administered in a capsule-based inhalation device and has not been approved for any indication in any jurisdiction.
The company presented the program at the American College of Chest Physicians Annual Meeting 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
db56b62487· 2026-10-15 19:19 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前